• 3 years ago
Amid questions raised by experts and Opposition over the restricted use approval given to Covaxin despite no efficacy data from Phase III trials, Health Ministry in its press conference addressed safety issues regarding Covaxin. Here's what it said.

Category

ЁЯЧЮ
News

Recommended